<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006157.pub2" GROUP_ID="LUNGCA" ID="806406031412131728" MERGED_FROM="" MODIFIED="2008-09-18 22:46:28 +0200" MODIFIED_BY="Karen Hovhannisyan" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-18 22:44:37 +0200" NOTES_MODIFIED_BY="Karen Hovhannisyan" REVIEW_NO="SB1" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-09-18 22:46:28 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TITLE>Chemotherapy and surgery versus surgery alone in non-small cell lung cancer</TITLE>
<CONTACT>
<PERSON ID="13675" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Burdett</LAST_NAME>
<SUFFIX/>
<POSITION>Research Scientist</POSITION>
<EMAIL_1>sb@ctu.mrc.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit</ORGANISATION>
<ADDRESS_1>222 Euston Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW1 2DA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 20 7670 4722</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 20 7670 4816</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="13675" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Burdett</LAST_NAME>
<SUFFIX/>
<POSITION>Research Scientist</POSITION>
<EMAIL_1>sb@ctu.mrc.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit</ORGANISATION>
<ADDRESS_1>222 Euston Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW1 2DA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 20 7670 4722</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 20 7670 4816</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8177" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Lesley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stewart</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>ls536@york.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Reviews and Dissemination</DEPARTMENT>
<ORGANISATION>University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP>YO10 5DD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)1904 321093</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0)1904 321041</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16832" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Larysa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rydzewska</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinator, Individual Patient Data Meta-analysis Methods Group</POSITION>
<EMAIL_1>lhr@ctu.mrc.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://www.ctu.mrc.ac.uk/cochrane/ipdmg</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Meta-analysis Group</DEPARTMENT>
<ORGANISATION>MRC Clinical Trials Unit</ORGANISATION>
<ADDRESS_1>222 Euston Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW1 2DA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 (0) 207 670 4721</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 (0) 207 670 4816</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-18 22:46:28 +0200" MODIFIED_BY="Karen Hovhannisyan" NOTES="&lt;p&gt;Minor update: 23/05/07&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="9" MONTH="4" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="18" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="9" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-18 22:44:37 +0200" MODIFIED_BY="Karen Hovhannisyan">
<SUMMARY MODIFIED="2008-09-18 22:44:37 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TITLE MODIFIED="2008-09-18 22:44:37 +0200" MODIFIED_BY="Karen Hovhannisyan">The pre-operative chemotherapy might increase survival in patients with non-small cell lung cancer when compared to surgery alone</TITLE>
<SUMMARY_BODY>
<P>The results of this systematic review suggest that pre-operative chemotherapy might increase survival in patients with non-small cell lung cancer when compared to surgery alone. However, an individual patient data systematic review and meta-analysis is needed to give us a more reliable assessment of the size of benefits and to explore whether pre-operative chemotherapy may be more or less effective for particular types of patients. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The role of pre-operative chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC) was not clear. A systematic review and quantitative meta-analysis were therefore undertaken to evaluate the available evidence from randomised trials.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effect of pre-operative chemotherapy on survival in patients with non-small cell lung cancer. If adequate data are available, to investigate whether or not pre-defined patient subgroups benefit more or less from pre-operative chemotherapy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE and CANCERLIT searches for randomised controlled trials (RCTs) were supplemented by information from trial registers and by handsearching relevant meeting proceedings and by discussion with relevant trialists and organisations. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>RCTs were eligible for inclusion provided the patients had been randomised between chemotherapy followed by surgery versus surgery alone and that the method of randomisation precluded prior knowledge of the treatment to be assigned.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>A systematic review and meta-analysis based on aggregate data extracted from trial publications was carried out to assess the effectiveness of pre-operative chemotherapy in NSCLC. This involved identifying eligible RCTs and extracting aggregate data from the abstracts or reports of these RCTs. Hazard ratios were calculated from published summary statistics and then combined to give pooled estimates of treatment efficacy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twelve eligible RCTs were identified. Data were available from seven RCTs including 988 patients (75% of eligible patients). Pre-operative chemotherapy increased survival with a hazard ratio of 0.82 (95%CI 0.69-0.97) P = 0.022. This is equivalent to an absolute benefit of 6%, increasing overall survival across all stages of disease from 14% to 20% at 5 years. There was no evidence of statistical heterogeneity (P = 0.980, I<SUP>2 </SUP>= 0).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This analysis shows a significant increase in survival attributable to pre-operative chemotherapy. This is currently the best estimate of the effectiveness of this therapy, but is based on a small number of trials and patients. This analysis was unable to address important questions such as whether particular types of patients may benefit more or less from pre-operative chemotherapy or whether the early stopping of a number of included RCTs impacted on the results. These issues may be addressed by an ongoing individual patient data (IPD) meta-analysis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Worldwide, more than a million new cases of lung cancer are diagnosed each year (<LINK REF="REF-Parkin-2001" TYPE="REFERENCE">Parkin 2001</LINK>), around 80% of which are of non-small cell type (<LINK REF="REF-Rankin-1986" TYPE="REFERENCE">Rankin 1986</LINK>), comprising adenocarcinomas, squamous cell and large cell carcinomas. Many patients are diagnosed when they already have an advanced form of the disease and as a consequence, five-year survival across all stages of disease is around 14% (<LINK REF="REF-Greenlee-2000" TYPE="REFERENCE">Greenlee 2000</LINK>). Surgery is generally regarded as the best treatment option, but only around 25% of NSCLC tumours are suitable for potentially curative resection (<LINK REF="REF-van-Zandwijk--2001" TYPE="REFERENCE">van Zandwijk 2001</LINK>). A further 20% of patients with locally advanced disease undergo radical thoracic radiotherapy. The remaining patients, with late stage or metastatic disease, are usually treated palliatively.</P>
<P>The role of chemotherapy in treating non-small cell lung cancer (NSCLC) has been extensively tested in clinical trials since the 1960's, with reported results being both beneficial and detrimental. An individual patient data (IPD) meta-analysis (<LINK REF="REF-NSCLCCG-1995" TYPE="REFERENCE">NSCLCCG 1995</LINK>) published in 1995, which is currently being updated (<LINK REF="REF-Burdett-2005" TYPE="REFERENCE">Burdett 2005</LINK>), found some evidence that chemotherapy given after surgery may improve survival. However, this project did not explore the use of chemotherapy given before surgery as few trials had been completed at that time.</P>
<P>The proposed benefits of preoperative chemotherapy are a reduction in tumour size such that tumours become easier to remove surgically, and inoperable tumours becoming potentially operable. Preoperative chemotherapy may also assist the early eradication of metastases that are clinically undetectable, which could lead to better control of distant recurrence. Chemotherapy given before surgery may also be better tolerated than postoperative chemotherapy, as the patient is more able to cope with side effects when not recovering from major surgery.</P>
<P>There are, however, proposed disadvantages to this treatment. Whilst the patient is receiving chemotherapy, a potentially curative operation is being delayed. If the chemotherapy being given is ineffective or only minimally effective, this delay could prove detrimental and could lead to the disease spreading (<LINK REF="REF-Faber-1994" TYPE="REFERENCE">Faber 1994</LINK>; <LINK REF="REF-Friedland-1995" TYPE="REFERENCE">Friedland 1995</LINK>; <LINK REF="REF-Ginsberg-1995" TYPE="REFERENCE">Ginsberg 1995</LINK>).</P>
<P>Preoperative chemotherapy has shown a benefit in other disease areas. An individual patient data (IPD) meta-analysis of preoperative chemotherapy in invasive bladder cancer (<LINK REF="REF-ABC-MA-2005" TYPE="REFERENCE">ABC MA 2005</LINK>) has shown a 14% relative improvement in overall survival (P = 0.003) for patients receiving the treatment, while a systematic review of published aggregate data in oesophageal cancer (<LINK REF="REF-Malthaner-2003" TYPE="REFERENCE">Malthaner 2003</LINK>) showed a significant benefit of the treatment at five years (P = 0.02). </P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the efficacy of chemotherapy given before surgery in patients with NSCLC</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Only randomised controlled trials were eligible for inclusion. Trials should have been properly randomised in a way which precluded prior knowledge of treatment assignment (excluding trials which allocated treatment by pseudo-random methods such as birthdate). Trials should have aimed to randomise patients with NSCLC between chemotherapy before surgery or surgery alone. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult patients with NSCLC who were randomised to receive chemotherapy before surgery or surgery alone. Patients must not have received prior chemotherapy or had any prior malignancy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Chemotherapy followed by surgery versus surgery alone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Overall survival<BR/>Disease-free survival</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>RCTs were identified in January 2005 by computerised bibliographic searches of MEDLINE using a modified version of the Cochrane Collaboration optimal search strategy [<LINK REF="REF-Dickersin-1995" TYPE="REFERENCE">Dickersin 1995</LINK>], supplemented with handsearches of meetings abstracts, bibliographies of books, reviews and specialist journals. Trial registers (Clinicaltrials.gov, Cancer.gov, MetaRegister and United Kingdom Coordinating Committee for Cancer Research) were also searched. Searches were updated in August 2005 to identify new trials and assess the status of ongoing trials.</P>
<P>Electronic search strategy:</P>
<P>1 Randomised Controlled Trial.pt.<BR/>2 exp Randomised Controlled Trials/<BR/>3 exp Random Allocation/<BR/>4 exp Double-Blind Method/<BR/>5 exp Single-Blind Method/<BR/>6 1 or 2 or 3 or 4 or 5<BR/>7 clinical trial.pt.<BR/>8 exp Clinical Trials/<BR/>9 clin$ with trial.ab,ti.<BR/>10 (sing$ or doubl$ or trebl$ or tripl$ with blind$ or mask$).ab, ti.<BR/>11 exp Placebos/<BR/>12 placebo$.ab.ti.<BR/>13 random$.ab,ti.<BR/>14 exp Research Design/<BR/>15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14<BR/>16 exp Carcinoma/<BR/>17 exp Lung Neoplasms/<BR/>18 (lung adj carcinoma$).ab.ti.<BR/>19 (lung adj cancer$).ab,ti.<BR/>20 (lung adj neoplasm$).ab,ti.<BR/>21 cancer with lung.ab,ti.<BR/>22 carcinoma with lung.ab,ti.<BR/>23 16 or 17<BR/>24 18 or 19 or 20 or 21 or 22<BR/>25 exp Drug Therapy/<BR/>26 drug therapy.ab,ti.<BR/>27 chemotherapy.ab,ti.<BR/>28 25 or 26 or 27<BR/>29 exp radiotherapy/<BR/>30 radiotherapy.ab,ti.<BR/>31 29 or 30<BR/>32 exp surgery/<BR/>33 surgery.ab,ti.<BR/>34 32 or 33<BR/>35 28 or 31 or 34<BR/>36 6 or 15<BR/>37 36 and 24 and 35</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>One author (SB) reviewed potential trials for inclusion, two authors (SB, LR) extracted data from the published manuscripts, where there was disagreement this was settled by discussion. For each trial, the method of randomisation and allocation concealment was recorded, as was the level of follow-up. In addition, data on surgery, chemotherapy and patient characteristics were collected. </P>
<P>Participants<BR/>For each trial, data on the number of patients randomised, analysed and excluded from the investigator's analyses were extracted. The distribution of patients by age, stage, histology, grade and performance status was also assessed. </P>
<P>Interventions<BR/>Data on the type of surgery performed was collected as was the dose, number of cycles and cycle length of chemotherapy.</P>
<P>Outcomes <BR/>The primary outcome was overall survival and disease-free survival was the secondary outcome. </P>
<P>For meta-analyses of the time-to-event outcomes (survival and disease-free survival), the most appropriate statistic is the hazard ratio (HR). If provided in a trial report, the HR and associated variances were used directly in the meta-analysis. Alternatively, using the methods described in <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK> they were estimated indirectly from other summary statistics (95% Confidence Intervals {CIs}, P values, total number of events) or from data extracted from published Kaplan-Meier curves [<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>]. In the latter method, the numbers at risk are adjusted (reduced), where appropriate, to allow for immature follow-up [<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>]. Where it was feasible, a number of methods were used to indirectly estimate the trial HR, to check its reliability. The estimated log HR and variance were then combined across all trials using the fixed-effect model to give a pooled HR [<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>]. This represents the overall risk of an event on pre-operative chemotherapy followed by surgery versus surgery alone. </P>
<P>Absolute effects on survival were calculated from the proportion event-free in the control group and the HR or OR for the particular outcome (exp[ln(proportion event free)xHR)]. </P>
<P>Chi squared tests for heterogeneity and the I<SUP>2</SUP> statistic were used to test for statistical heterogeneity and inconsistency in results across all trials. The overall and within group chi squared tests for heterogeneity were also used to assess the consistency of effect between different subsets of trials and are referred to as chi squared tests for interaction. These tests were aimed primarily at detecting differences in size of effect, rather than direction. Thus, to explore variation in the chemotherapy treatments used between trials, which can introduce statistical heterogeneity, supplementary analyses were performed on pre-specified trial groups. These groupings were by chemotherapy regimen (platinum-based + vinca alkaloid/etoposide versus platinum-based + taxane versus other platinum regimen), disease stage and planned post-operative treatment. </P>
<P>In all tests of significance a two-sided P value is given.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Searches identified 12 randomised trials [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-De-Boer-1999" TYPE="STUDY">De Boer 1999</LINK>; <LINK REF="STD-MRC-BLT-2004" TYPE="STUDY">MRC BLT 2004</LINK>; <LINK REF="STD-Yi-2003" TYPE="STUDY">Yi 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>; <LINK REF="STD-Wu-2002" TYPE="STUDY">Wu 2002</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>; <LINK REF="STD-ChEST-2005" TYPE="STUDY">ChEST 2005</LINK>] (1310 patients) that were potentially eligible for inclusion. No useful data on the outcomes of interest could be obtained for five of these trials (403 patients). Three [<LINK REF="STD-Wu-2002" TYPE="STUDY">Wu 2002</LINK>; <LINK REF="STD-Yi-2003" TYPE="STUDY">Yi 2003</LINK>; <LINK REF="STD-ChEST-2005" TYPE="STUDY">ChEST 2005</LINK>] were published as abstracts and did not contain the relevant information, one [<LINK REF="STD-De-Boer-1999" TYPE="STUDY">De Boer 1999</LINK>] was a full publication but contained no relevant statistics or survival curves. The final trial [<LINK REF="STD-MRC-BLT-2004" TYPE="STUDY">MRC BLT 2004</LINK>] had an option for patients randomised to chemotherapy to receive this either before or after surgery. All the patients were analysed together and it was not possible to extract the data on just the small number of patients who received neo-adjuvant chemotherapy.</P>
<P>Seven trials [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] including 988 patients and representing 75% of the randomised evidence were therefore included in the analysis for overall survival. </P>
<P>Disease-free survival was reported for 3 of these trials [<LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] (457 patients).</P>
<P>The seven RCTs included in this review were carried out between 1985 and 2004 with the number of randomised patients ranging from 26 to 373. A variety of chemotherapy regimens were used in the RCTs but all patients received platinum-based chemotherapy. Patients were also reported to have had a variety of treatments post-operatively, 2 RCTs [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>] reported patients receiving post-operative chemotherapy on the pre-operative chemotherapy arm only, 3 RCTs [<LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>] reported patients receiving post-operative radiotherapy on both arms, 1 RCT [<LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>] reported post-operative radiotherapy on both arms and post-operative chemotherapy on the pre-operative chemotherapy arm. 1 RCT [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] did not report any post-operative treatment. All RCTs reported a combination of patients with complete and incomplete resection. 4 RCTs [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] included all stages of disease while 3 RCTs [<LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>] included stage III only.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Once the seven eligible RCTs were identified, they were assessed for quality using a Component Approach. This involved looking at the methodological aspects of each trial using the CONSORT statement [<LINK REF="REF-Begg-C-1996" TYPE="REFERENCE">Begg C 1996</LINK>] as a guide of which variables to assess. Full details of the assessment are in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Method of randomisation<BR/>No RCTs gave full details of randomisation. Four RCTs [<LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>] reported to have randomised patients centrally through a data centre and the remaining three RCTs reported to be 'randomised'. No further trials reported concealment of allocation, but there were two trials [<LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>] which used a central telephone, which would imply a level of allocation concealment. A further two RCTs [<LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] reported details of their stratification factors. Three additional RCTs [<LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] describe their sample size calculations, and the remaining RCTs do not report any of these factors.</P>
<P>Completeness of data<BR/>Six RCTs did not reach their planned accrual for a variety of reasons. Two RCTs [<LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>] closed early due to poor accrual, three RCTs [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>] closed early due to a significant difference between the treatments being tested in the trial, one further RCT [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] closed early due to the results of other trials. The remaining RCT [<LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>] appears to have reached target accrual.</P>
<P>Only two RCTs [<LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] reported patient exclusions. They are the two largest RCTs identified for inclusion in the systematic review and both excluded around 5% of patients before analysis. In both RCTs, all exclusions were due to patients being found to be ineligible post-randomisation. None of the other RCTs reported patient exclusions.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Data were extracted and analyses performed using all methods possible according to the 'Parmar Method' [<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>]. Survival data were available for all seven RCTs (988 patients). For five RCTs [<LINK REF="STD-Dautzenberg-1990" TYPE="STUDY">Dautzenberg 1990</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>] the only data available was data extracted from the published curves. For one RCT [<LINK REF="STD-Depierre-2002" TYPE="STUDY">Depierre 2002</LINK>] the P value and number of events and the published curve were available and for one RCT [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] the hazard ratio and confidence intervals were available.</P>
<P>Overall Survival (Comparison 1, Outcome 1)<BR/>The forest plot for overall survival shows the estimated hazard ratios for survival and reveals that although the confidence intervals for individual trial results are wide and the results of all trials are inconclusive, all but one hazard ratio estimate were in favour of pre-operative chemotherapy. </P>
<P>There was no clear evidence of statistical heterogeneity, (chi squared test for heterogeneity = 1.141, (P = 0.980), I<SUP>2 </SUP>= 0) indicating that there is no obvious difference between trial results, and that the trials are similar enough to be combined.</P>
<P>The combined results showed a significant increase in survival associated with the use of pre-operative chemotherapy (P = 0.022). The hazard ratio of 0.82 (95% CI 0.69-0.97), represents an overall 18% relative reduction in the risk of death on pre-operative chemotherapy. This is equivalent to an absolute improvement of 6% at five years, increasing overall survival from 14% to 20%. However, survival varies by stage of disease and using the baseline survival from the various stages gives a range in benefit of 3% to 7% for individual stages of disease [<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>]. </P>
<P>As specified in the protocol, overall survival was also analysed using the random-effects model. This resulted in the same HR of 0.82 (95% CI 0.69-0.97), as would be expected with a set of homogeneous trials.</P>
<P>Sensitivity analysis for overall survival (Comparison 1, Outcome 2)<BR/>The overall hazard ratio (0.82) was very similar to the hazard ratios of the two largest included RCTs (Depierre HR = 0.83, SWOG S9900 HR = 0.84). To ensure the result of the meta-analysis was not being driven entirely by the results of these two RCTs, a sensitivity analysis was undertaken whereby these two RCTs were taken out of the analysis. The hazard ratio for the remaining RCTs was 0.79 (95%CI 0.59-1.08), which is reasonably similar to the hazard ratio for the overall result, and almost reached statistical significance. As would be expected the confidence intervals were wider given the reduced patient numbers.</P>
<P>Analysis of other outcomes<BR/>The protocol pre-specified that local recurrence-free survival, distant recurrence-free survival and overall recurrence-free survival would be analysed if sufficient data were available. The only endpoint for which sufficient data were reported was disease-free survival (Comparison 2, Outcome 1).</P>
<P>For this endpoint, data could be extracted from the publications of three RCTs (457 patients) [<LINK REF="STD-JCOG9209-2003" TYPE="STUDY">JCOG9209 2003</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>]. Hazard ratios were estimated using the Parmar Method [Parmar 1998] and the combined results showed a significant increase in disease-free survival associated with the use of pre-operative chemotherapy (P = 0.039). The hazard ratio of 0.78 (95% CI 0.52-0.99) represents an overall 22% relative reduction in the risk of progression of disease or death on pre-operative chemotherapy. There was some evidence of statistical heterogeneity, (chi squared test for heterogeneity = 5.416, (P = 0.067)), and the I<SUP>2</SUP> of 63% further suggested variability between the trial results. However, it is unwise to draw conclusions from this analysis as it is only based on three trials and 457 patients (46% of available data). The results are undoubtedly being driven by the results of the largest RCT [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>], which accounts for three quarters of the patients included in this analysis.</P>
<P>Overall survival by chemotherapy type (Comparison 1, Outcome 3)<BR/>The protocol pre-specified that if enough data were available, an analysis would be carried out according to the type of chemotherapy given. All patients received a platinum-based chemotherapy - either cisplatin or carboplatin which was combined with other agents. These other agents were split into the following groups, according to the way the chemotherapy works. 'Platinum + vinca alkaloid/etoposide', 'platinum + taxane' and 'other platinum regimen'. The three groups all have very similar hazard ratios and no individual group is significant. The test for interaction was chi squared<SUB>(1)</SUB> = 0.12, P = 0.999 indicating there is no clear evidence of a difference of treatment effect shown by chemotherapy group.</P>
<P>Overall survival by stage of disease (Comparison 1, Outcome 4)<BR/>The seven RCTs randomised either a mix of all stages of patients, up to stage III (four RCTs) or only stage III patients (three RCTS). A simple analysis could be performed at trial level to see if there was any difference in the performance of treatment in these two groups.</P>
<P>The test for interaction chi squared<SUB>(1) </SUB>= 0.322, P = 0.570 indicated there was no difference in treatment effect for the trials that recruited only stage III patients and those that included a wider range of stages. Information on the proportion of stages included in the trials was available for three of these four RCTs. 34% were stage I, 26% were stage II and 39% were stage III with no single stage of disease dominating this analysis.</P>
<P>Overall survival by post-operative treatment (Comparison 1, Outcome 5)<BR/>Five of the seven trials reported that patients also received post-operative treatment, which was either radiotherapy or chemotherapy. A trial level analysis explored whether there was any difference in the effect of treatment between the two groups, i.e. was the observed effect of pre-operative chemotherapy influenced or moderated by the post-operative therapy? Where radiotherapy was given post-operatively, it was given to patients on both arms. However, when chemotherapy was given post-operatively, it was only given to those patients on the pre-operative chemotherapy arm. Because of this inconsistency, and because of the small numbers of patients included in this analysis, the analysis should be viewed as exploratory.</P>
<P>The test for interaction chi squared<SUB>(1) </SUB>= 0.308, P = 0.578, indicated that based on the data available, there was no clear evidence of a difference in the effectiveness of pre-operative chemotherapy between those trials that gave radiotherapy post-operatively and those that gave further chemotherapy post-operatively.</P>
<P>A further trial level analysis of those patients who received any post-operative treatment compared with those who received no further treatment was considered. However, only one RCT [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] reported giving no further treatment and therefore this analysis was not carried out.</P>
<P>Toxicity and quality of life assessment<BR/>Quality of life was not assessed in any of the seven trials. There was however, some information about toxicity of the treatment. Three of the trials reported leukopenia, anaemia, alopecia and nausea and vomiting to be common mild side effects of the chemotherapy given. One further trial reported that there were 'no major toxic effects' associated with chemotherapy. As these side effects were not reported as severe, one must surmise that the chemotherapy was well tolerated by the patients.</P>
<P>Tests for publication bias<BR/>A formal test for publication bias was carried out . The P value from Begg's test was 0.293 and the P value from Egger's test was 0.941, both suggesting there was no significant publication bias. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> is fairly symmetrical, with no clear indication that small negative studies are missing, and so does not suggest publication bias. In fact, the plot might suggest that small studies in favour of pre-operative chemotherapy are missing. However, with only seven trials included, which is less than the minimum recommended number of ten trials [<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>] , this analysis is likely to be unreliable. Also, we are already aware that some trials, i.e. the five eligible but excluded RCTs that have already been identified, are missing from the analysis and cannot be included (as there are no results for them), it is not clear where these would fit on Begg's graph. However, from this limited analysis, there is no indication of significant publication bias amongst the included RCTs.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>At the outset of this project, the efficacy of chemotherapy given before surgery versus surgery alone in patients with NSCLC had not been formally addressed in a systematic review. Due to the presence of large, ongoing trials or very recently closed trials, it was decided to carry out a systematic review and meta-analysis of the published data as a means of summarising current evidence on the effectiveness of this intervention, pending the completion of an ongoing individual patient data (IPD) meta-analysis.</P>
<P>Unfortunately the limitations of a systematic review based on data extracted from published RCTs meant that despite finding 12 eligible RCTs that included 1310 patients, the meta-analysis was limited to data that could be extracted from the publications of only seven RCTs. Of the five RCTs that could not be included, four lacked relevant statistics or survival curves and one RCT could not be included as the patients who received pre-operative chemotherapy were not reported independently from those patients who were treated with post-operative chemotherapy. The seven remaining RCTs included 988 patients and represented 75% of the known randomised evidence.</P>
<P>The RCTs included in this systematic review all seem to be of fairly good methodological quality. All RCTs appear to be randomised, but the reporting of methods of allocation concealment and stratification factors is rather sparse. Patient exclusion is not likely to have introduced bias in this review, as only two RCTs appear to have excluded patients and in both cases, this represents only 5% of patients. However, the assessment of quality in systematic reviews of published data relies on the quality of information reported in the trial publications</P>
<P>For the main endpoint of overall survival, the meta-analysis showed a significant benefit to chemotherapy given before surgery over surgery alone. This is equivalent to an absolute benefit of 6% at five years. Although all trials randomised patients to chemotherapy and surgery versus surgery alone, there was a wide range of treatments given post-operatively, sometimes in both arms, sometimes in the chemotherapy alone arm. There is no suggestion that pre-operative chemotherapy is more or less effective depending upon whether chemotherapy or radiotherapy was given after surgery (test for interaction = chi squared<SUB>(1) </SUB>= 0.308, P = 0.578). However, data were only available for five out of seven trials and included only 298 patients, therefore this result has low power, is extremely limited and should be interpreted extremely cautiously. There was also no suggestion that patients performed better or worse depending upon which type of chemotherapy they were given pre-operatively (P = 0.999).</P>
<P>There was no suggestion of statistical heterogeneity (P = 0.980, I<SUP>2 </SUP>= 0) or publication bias (Begg P = 0.293, Egger P = 0.941) in the results for overall survival. There was more heterogeneity reported for disease-free survival (P = 0.067, I<SUP>2 </SUP>= 63), but this analysis was very limited due to the small number of RCTs and patients included. </P>
<P>No meaningful patient level subgroup analyses could be performed based upon the data reported in the publications. This illustrates the difficulty of trying to explore patient level characteristics using aggregate data. The RCTs included in this review reported patient level characteristics in a number of different ways, making comparisons between the trials impossible. The only practical way to explore these patient subgroups is by using IPD and this will be done in the ongoing IPD meta-analysis.</P>
<P>No formally measured quality of life data were reported in any of the RCT publications, therefore no conclusions could be drawn beyond a description of the toxicity reported, which may have impacted on patients' quality of life. There did not appear to be any serious toxicity associated with chemotherapy from the information reported.</P>
<P>Eight of the twelve RCTs initially identified and six of the seven RCTs included in this systematic review were stopped early. If recruitment to trials is stopped due to significant differences between treatments or a 'random high', this can lead to excessive false positive results [<LINK REF="REF-Green-1987" TYPE="REFERENCE">Green 1987</LINK>], but this problem can be overcome to some extent by collecting extra follow-up data. Two RCTs [<LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="STD-Rosell-1994" TYPE="STUDY">Rosell 1994</LINK>] that stopped due to an observed significant benefit on the pre-operative chemotherapy arm reported their results twice, both in 1994, then in 1998 [<LINK REF="REF-Roth-1998" TYPE="REFERENCE">Roth 1998</LINK>] and 1999 [<LINK REF="REF-Rosell-1999" TYPE="REFERENCE">Rosell 1999</LINK>]. In both cases the treatment effect lessened over time, and in one case [<LINK REF="STD-Roth-1994" TYPE="STUDY">Roth 1994</LINK>; <LINK REF="REF-Roth-1998" TYPE="REFERENCE">Roth 1998</LINK>] the P value changed from P = &lt;0.008 to P = 0.056, which borders statistical significance. The use of IPD would allow for the collection of additional follow-up and may go some way towards balancing this potential problem, the ongoing IPD meta-analysis may help to address this issue.</P>
<P>In August 2005, as this project was nearing completion, literature searches were carried out for a second time. This time, a systematic review by Berghmans et al [<LINK REF="REF-Berghmans-2005" TYPE="REFERENCE">Berghmans 2005</LINK>] of pre-operative chemotherapy and surgery versus surgery alone was identified. It reported six RCTs and 590 patients. It did not include two of the trials in this review [<LINK REF="STD-Sorensen-2005" TYPE="STUDY">Sorensen 2005</LINK>; <LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>]. However, it did include one additional trial [<LINK REF="REF-Pass-1992" TYPE="REFERENCE">Pass 1992</LINK>] that had been deemed ineligible for inclusion in this review. This additional trial randomised 27 patients to receive chemotherapy followed by surgery plus chemotherapy versus surgery followed by radiotherapy. This comparison was therefore confounded by the inclusion of radiotherapy in just one arm so that it is not possible to say whether any difference between arms is due to the addition of chemotherapy or radiotherapy. On this basis the trial was not considered eligible for inclusion in this review. Trials included in this review and Berghmans review are shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. The overall fixed effect hazard ratio for the review by Berghmans is 0.69 (95% CI 0.057-0.84) which is significantly in favour of treatment. This is a more extreme result than the result of this review (HR = 0.82, 95% CI 0.69-0.97), suggesting a 31% reduction in the risk of death with chemotherapy and surgery versus surgery alone. There is some heterogeneity between the trials they have used (P = 0.07), whereas this review reports no heterogeneity. Berghmans et al conclude that pre-operative chemotherapy is effective, but this should be confirmed by further studies.</P>
<P>Two further large RCTs have recently closed but are not yet reported, and one large RCT is ongoing. One large RCT included in this systematic review [<LINK REF="STD-SWOG9900-2005" TYPE="STUDY">SWOG9900 2005</LINK>] has only recently been reported as an abstract. It is hoped that these RCTs will be included in the ongoing IPD meta-analysis.</P>
<P>IPD meta-analyses are not reliant on published information and all twelve RCTs initially identified as eligible are included in the ongoing IPD meta-analysis. The inclusion of recently closed and ongoing trials brings the total of RCTs which potentially can be included to fifteen. IPD meta-analyses allow the collection of additional follow-up, which will go some way towards addressing the potential problems of RCTs that have stopped early. It will also allow other outcomes such as disease-free survival to be investigated further.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The results of this systematic review suggest there may be a benefit from pre-operative chemotherapy, but an IPD systematic review and meta-analysis should give us a more reliable estimate of any treatment effect. This is also the only reliable way to carry out subgroup analyses to address whether pre-operative chemotherapy may be more or less effective for particular types of patients. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Although the systematic review reported here is limited, it represents a comprehensive and up to date systematic review of the published data and suggests a significant survival benefit for patients with NSCLC who receive pre-operative chemotherapy compared to those who do not. The value of this treatment will be assessed further through the ongoing IPD meta-analysis.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to the British Medical Research Council for funding this work. We would like to thank the Cochrane Lung Review Group with for their help with the translation of a Chinese publication. We would also like to thank Jayne Tierney and Claire Vale for their extensive comments on this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Sarah Burdett designed the protocol, identified RCTs for inclusion, extracted data from the trial publications, performed the analyses and wrote the final review.</P>
<P>Lesley Stewart advised on the protocol design and interpretation of results and commented on the review.</P>
<P>Larysa Rydzewska extracted the data from the trial publications.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dautzenberg-1990" NAME="Dautzenberg 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dautzenberg B, Benichou J, Allard P, Lebeau B, Coetmeur D, Brechot J-M, et al</AU>
<TI>Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>65</VL>
<PG>2435-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Depierre-2002" NAME="Depierre 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al</AU>
<TI>Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>1</NO>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JCOG9209-2003" NAME="JCOG9209 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, et al</AU>
<TI>A randomised trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIa N2 non-small cell lung cancer</TI>
<SO>The Journal of Thoracic and Cardiothoracic Surgery</SO>
<YR>2003</YR>
<VL>125</VL>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosell-1994" NAME="Rosell 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosell R, Maestre J, Font A, Moreno I, Molina F, Milla A, et al</AU>
<TI>A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>3 Suppl 4</NO>
<PG>28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-1994" NAME="Roth 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roth JA, Fosella F, Komaki R, Ryan B, Putnam Jr JB, Soo Lee J, et al</AU>
<TI>A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1994</YR>
<VL>86</VL>
<NO>9</NO>
<PG>673-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorensen-2005" NAME="Sorensen 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen JB, Riska H, Ravn J, Hansen O, Palshof T, Rytter C, et al</AU>
<TI>Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>7146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SWOG9900-2005" NAME="SWOG9900 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Pisters K, Vallieres E, Bunn P, Crowley J, Ginsberg R, Ellis P, et al</AU>
<TI>S9900: A phase III trial of surgery alone or surgery plus pre-operative (pre-op) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>LBA7012</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-ChEST-2005" NAME="ChEST 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scagliotti GV on behalf of Ch.E.S.T. Investigators</AU>
<TI>Preliminary results of Ch.E.S.T.: A phase III stdy of surgery alone or surgery plus pre-operative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer (NSCLC).</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>LBA7023</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boer-1999" NAME="De Boer 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Boer RH, Smith IE, Pastorino U, O'Brien ME, Ramage F, Ashley S, Goldstraw P</AU>
<TI>Pre-operative chemotherapy in early stage resectable non-small cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial.</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>79</VL>
<PG>1514-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-BLT-2004" NAME="MRC BLT 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, Rudd RM, Spiro SG</AU>
<TI>Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>173-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2002" NAME="Wu 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Gu L, Weng Y, Feng W, Cheng C</AU>
<TI>Neo-adjuvant chemotherapy with docetaxel plus carboplatin for non-small cell lung cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2003" NAME="Yi 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yi X, Zhang R, Ding J, Gao W, Ma Q, Zhong C</AU>
<TI>A clinicopathologic study on neoadjuvant chemotherapy in the treatment of non-small cell lung cancer</TI>
<SO>Chinese Journal of Lung Cancer</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>2</NO>
<PG>124-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-ABC-MA-2005" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="ABC MA 2005" TYPE="JOURNAL_ARTICLE">
<AU>Advanced Bladder Cancer (ABC) Meta-analysis Collaboration</AU>
<TI>Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data</TI>
<SO>European Urology</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>2</NO>
<PG>202-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-C-1996" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Begg C 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting randomized controlled trials. The CONSORT statement</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-2005" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Berghmans 2005" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al</AU>
<TI>Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature</TI>
<SO>Lung Cancer</SO>
<YR>2005</YR>
<VL>49</VL>
<PG>13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burdett-2005" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Burdett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burdett S, Stewart L, Stephens R, Auperin A, Pignon JP, Le Chevalier T</AU>
<TI>Letter to the Editor</TI>
<SO>Lung Cancer</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>1</NO>
<PG>149-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1995" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Dickersin 1995" TYPE="BOOK_SECTION">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>Systematic Reviews</SO>
<YR>1995</YR>
<PG>17-36</PG>
<ED>Chalmers I, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faber-1994" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Faber 1994" TYPE="JOURNAL_ARTICLE">
<AU>Faber LP</AU>
<TI>Current status of neoadjuvant therapy of non-small cell lung cancer</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>6</NO>
<PG>355S-8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedland-1995" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Friedland 1995" TYPE="JOURNAL_ARTICLE">
<AU>Friedland DM, Comis RL</AU>
<TI>Perioperative therapy of non-small cell lung cancer: A review of adjuvant and neo-adjuvant approaches</TI>
<SO>Seminars in Oncology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>6</NO>
<PG>571-581</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ginsberg-1995" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Ginsberg 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg RJ</AU>
<TI>Neoadjuvant (induction) treatment for non-small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>Suppl 2</NO>
<PG>S33-S40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-1987" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Green 1987" TYPE="JOURNAL_ARTICLE">
<AU>Green SJ, Fleming TR</AU>
<TI>Effects on overviews of early stopping rules for clinical trials</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>361-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenlee-2000" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Greenlee 2000" TYPE="JOURNAL_ARTICLE">
<AU>Greenlee RT, Murray T, Bolden S, Wingo PA</AU>
<TI>Cancer Statistics</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>1</NO>
<PG>7-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malthaner-2003" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Malthaner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Malthaner R, Fenlon D</AU>
<TI>Preoperative chemotherapy for resectable thoracic esophageal cancer</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<VL>Issue 4</VL>
<NO>Art. No.: 001556</NO>
<PG>DOI: 10.1002/14651858.CD001556</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NSCLCCG-1995" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="NSCLCCG 1995" TYPE="JOURNAL_ARTICLE">
<AU>Non-small Cell Lung Cancer Collaborative Group</AU>
<TI>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2001" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Parkin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM</AU>
<TI>Global cancer statistics in the year 2000</TI>
<SO>Lancet Oncology</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>9</NO>
<PG>533-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pass-1992" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Pass 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J</AU>
<TI>Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1992</YR>
<VL>53</VL>
<PG>992-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rankin-1986" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Rankin 1986" TYPE="BOOK_SECTION">
<AU>Rankin EM</AU>
<TI>Non-small cell lung cancer</TI>
<SO>Randomised clinical trials in cancer: A critical review by site</SO>
<YR>1986</YR>
<PG>447-492</PG>
<ED>Slevin ML, Staquet MJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosell-1999" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Rosell 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rosell R, Gomez-Codina J, Camps C, Sanchez JJ, Maestre J, Padilla J, et al</AU>
<TI>Preresectional chemotherapy in stage IIIa non-small cell lung cancer: a 7 year assessemtn of a radnomized controlled trial</TI>
<SO>Lung Cancer</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roth-1998" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Roth 1998" TYPE="JOURNAL_ARTICLE">
<AU>Roth JA, Atkinson EN, Fossella F, Komaki R, Ryal MB, Putnam Jr JB, et al</AU>
<TI>Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<PG>189-208</PG>
<EN>2</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Zandwijk--2001" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="van Zandwijk  2001" TYPE="JOURNAL_ARTICLE">
<AU>van Zandwijk N</AU>
<TI>Neoadjuvant strategies for non-small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>S145-S150</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J.A., Collins R, Sleight P</AU>
<TI>Beta blockade during and after myocardial infarction: an overview of the randomized trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Dautzenberg-1990">
<CHAR_METHODS>
<P>1985-1987 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 patients<BR/>Stage I, II, III</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Cisplatin, cyclophosphamide and vindesine<BR/>Post-op chemo given on pre-op chemo arm only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Disease-free interval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Depierre-2002">
<CHAR_METHODS>
<P>1991-1997 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>373 patients<BR/>Stage I, II, IIIa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Cisplatin, mitomycin and ifosphamide<BR/>If surgery incomplete, patients received post-op RT (all patients) or chemo (pre-op chemo patients only)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Disease-free survival<BR/>Response rate<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-JCOG9209-2003">
<CHAR_METHODS>
<P>1993-1998 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>62 patients<BR/>Stage IIIa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Cisplatin and vindesine<BR/>If surgery incomplete, patients recevied post-op RT on both arms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Disease-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rosell-1994">
<CHAR_METHODS>
<P>1989-1991 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 patients<BR/>Stage IIIa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Cisplatin, mitomycin and ifosphamide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Disease-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roth-1994">
<CHAR_METHODS>
<P>1987-1993 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 patients<BR/>Stage IIIa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Cisplatin, cyclophosphamide and etoposide<BR/>If patients responded to pre-op chemo, 3 cycles given post-operatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sorensen-2005">
<CHAR_METHODS>
<P>1998-2004 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>90 patients<BR/>Stage Ia, IIa, IIb, IIIa/T3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Carboplatin and paclitaxel<BR/>If surgery incomplete patients received post-op RT on both arms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Disease-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SWOG9900-2005">
<CHAR_METHODS>
<P>1999-2004 RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>354 patients<BR/>Stage Ib, II, IIIa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Chemo + surgery vs surgery alone<BR/>Carboplatin and paclitaxel<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival<BR/>Overall survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-ChEST-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data could not be extracted - Not enough information in abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Boer-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data could not be extracted - No relevant statistics or survival curves in pulication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-BLT-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data could not be extracted -Trial treated patients with choice or pre- or post-op chemotherapy. No split between the two in manuscript</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data could not be extracted - Not enough information in abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data could not be extracted - Not enough information in abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dautzenberg-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Depierre-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-JCOG9209-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rosell-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Roth-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SWOG9900-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sorensen-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="1">
<TITLE>Assessment of methodological quality of included trials</TITLE>
<TABLE COLS="10" ROWS="8">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Randomisation method</P>
</TH>
<TH>
<P>Allocation concealed</P>
</TH>
<TH>
<P>Stratification</P>
</TH>
<TH>
<P>Outcomes reported</P>
</TH>
<TH>
<P>QOL assessed</P>
</TH>
<TH>
<P>Analyses methods</P>
</TH>
<TH>
<P>Survival plots shown</P>
</TH>
<TH>
<P>Patient exclusions</P>
</TH>
<TH>
<P>Stopped early?</P>
</TH>
</TR>
<TR>
<TD>
<P>Dautzenberg<BR/>1990</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>overall survival<BR/>disease-free interval</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>log rank test</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Roth 1994</P>
</TD>
<TD>
<P>lists and blocks</P>
</TD>
<TD>
<P>central data centre</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>overall survival</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>kaplan meier<BR/>log-rank test<BR/>cox model</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosell 1994</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>central telephone</P>
</TD>
<TD>
<P>by stage, location of tumour, histology, N2 lymph nodes</P>
</TD>
<TD>
<P>overall survival<BR/>disease-free survival</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>kaplan-meier<BR/>log-rank test<BR/>brookmeyer-crowley (CIs)</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Depierre 2002</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>central telephone</P>
</TD>
<TD>
<P>by centre</P>
</TD>
<TD>
<P>overall survival<BR/>disease-free survival<BR/>response rate<BR/>toxicity</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>kaplan-meier<BR/>log-rank test<BR/>cox model</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>8 on chemo arm<BR/>10 on no chemo arm<BR/>All ineligible and not analysed</P>
</TD>
<TD>
<P>no</P>
</TD>
</TR>
<TR>
<TD>
<P>JCOG9209 2003</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>overall survival<BR/>disease-free survival</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>kaplan-meier<BR/>log-rank test<BR/>chi-square</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Sorensen 2005</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>overall survival<BR/>disease-free survival</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>SWOG9900 2005</P>
</TD>
<TD>
<P>reported as 'randomised'</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>by stage</P>
</TD>
<TD>
<P>progression-free survival<BR/>overall survival</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>log-rank test</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>19 patients excluded from trial over both arms, all exclusions ineligible and not analysed</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="2">
<TITLE>5 year survival by stage</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH>
<P>Stage</P>
</TH>
<TH>
<P>5 year survival</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>New 5 year survival</P>
</TH>
</TR>
<TR>
<TD>
<P>Ia</P>
</TD>
<TD>
<P>75%</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>79%</P>
</TD>
</TR>
<TR>
<TD>
<P>Ib</P>
</TD>
<TD>
<P>55%</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P>61%</P>
</TD>
</TR>
<TR>
<TD>
<P>IIa</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>7%</P>
</TD>
<TD>
<P>57%</P>
</TD>
</TR>
<TR>
<TD>
<P>IIb</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>7%</P>
</TD>
<TD>
<P>47%</P>
</TD>
</TR>
<TR>
<TD>
<P>IIIa</P>
</TD>
<TD>
<P>15-35%</P>
</TD>
<TD>
<P>6-7%</P>
</TD>
<TD>
<P>21-42%</P>
</TD>
</TR>
<TR>
<TD>
<P>IIIb</P>
</TD>
<TD>
<P>5-10%</P>
</TD>
<TD>
<P>3-5%</P>
</TD>
<TD>
<P>8-15%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="3">
<TITLE>RCTs included in review by Berghmans et al compared with RCTs in Burdett et al</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH>
<P>RCTs in Berghmans</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>RCTs in Burdett</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
</TR>
<TR>
<TD>
<P>Dautzenberg 1990</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>Dautzenberg 1990</P>
</TD>
<TD>
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosell 1994</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>Rosell 1994</P>
</TD>
<TD>
<P>60</P>
</TD>
</TR>
<TR>
<TD>
<P>Roth 1994</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>Roth 1994</P>
</TD>
<TD>
<P>60</P>
</TD>
</TR>
<TR>
<TD>
<P>Depierre 2002</P>
</TD>
<TD>
<P>355</P>
</TD>
<TD>
<P>Depierre 2002</P>
</TD>
<TD>
<P>355</P>
</TD>
</TR>
<TR>
<TD>
<P>JCOG 9209 2003</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>JCOG 9209 2003</P>
</TD>
<TD>
<P>62</P>
</TD>
</TR>
<TR>
<TD>
<P>Pass 1992</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>SWOG 9900 2005</P>
</TD>
<TD>
<P>354</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Sorensen 2005</P>
</TD>
<TD>
<P>90</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Overall survival</NAME>
<IPD_OUTCOME CHI2="1.0356653320617322" CI_END="0.9735904103257645" CI_START="0.6934126299085985" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.8216446232269642" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.011623712472234019" LOG_CI_START="-0.15900825231092033" LOG_EFFECT_SIZE="-0.08531598239157717" NO="1" P_CHI2="0.9842240869466161" P_Q="1.0" P_Z="0.023261318795903353" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="495" WEIGHT="100.0" Z="2.2691152406645148">
<NAME>Hazard ratio plot for overall survival</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.9271922614544668" CI_START="0.36551861997408325" EFFECT_SIZE="1.0343806242412183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.4664512483465254" LOG_CI_START="-0.4370904946403902" LOG_EFFECT_SIZE="0.01468037685306762" ORDER="1" O_E="0.12" SE="0.5307448924342753" STUDY_ID="STD-Dautzenberg-1990" TOTAL_1="13" TOTAL_2="13" VAR="3.55" WEIGHT="2.6607704991755354"/>
<IPD_DATA CI_END="1.880947578039979" CI_START="0.4174194922007471" EFFECT_SIZE="0.8860836207049948" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.27437669194313985" LOG_CI_START="-0.37942727458640435" LOG_EFFECT_SIZE="-0.05252529132163224" ORDER="2" O_E="-0.82" SE="0.3840476863212843" STUDY_ID="STD-Roth-1994" TOTAL_1="28" TOTAL_2="32" VAR="6.78" WEIGHT="5.081696897016938"/>
<IPD_DATA CI_END="1.2390575167625308" CI_START="0.31833866295872504" EFFECT_SIZE="0.6280445153133193" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.09309146669310178" LOG_CI_START="-0.49711061211752117" LOG_EFFECT_SIZE="-0.20200957271220965" ORDER="3" O_E="-3.87" SE="0.3466876226407682" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="8.32" WEIGHT="6.235946634687452"/>
<IPD_DATA CI_END="1.070508202982253" CI_START="0.6405215276149929" EFFECT_SIZE="0.8280601122494511" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.029589999511146887" LOG_CI_START="-0.19346626924906055" LOG_EFFECT_SIZE="-0.08193813486895686" ORDER="4" O_E="-10.99" SE="0.13102435641608368" STUDY_ID="STD-Depierre-2002" TOTAL_1="179" TOTAL_2="176" VAR="58.25" WEIGHT="43.659121570978854"/>
<IPD_DATA CI_END="1.3049813788442566" CI_START="0.42715669920869875" EFFECT_SIZE="0.746613379411278" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11560431464526982" LOG_CI_START="-0.36941277809522216" LOG_EFFECT_SIZE="-0.12690423172497617" ORDER="5" O_E="-3.6" SE="0.2849014411490949" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="31" TOTAL_2="31" VAR="12.32" WEIGHT="9.233997901364113"/>
<IPD_DATA CI_END="1.6315917150066166" CI_START="0.4897438728581821" EFFECT_SIZE="0.8939027046780111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.21261149136432372" LOG_CI_START="-0.3100309887186818" LOG_EFFECT_SIZE="-0.04870974867717906" ORDER="6" O_E="-1.19" SE="0.3070027799227584" STUDY_ID="STD-Sorensen-2005" TOTAL_1="44" TOTAL_2="46" VAR="10.61" WEIGHT="7.952330984859839"/>
<IPD_DATA CI_END="1.1778839369590117" CI_START="0.5989166003991823" EFFECT_SIZE="0.8399132355120356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.07110249926132672" LOG_CI_START="-0.22263364924364623" LOG_EFFECT_SIZE="-0.07576557499115974" ORDER="7" O_E="-5.86" SE="0.17254206764920632" STUDY_ID="STD-SWOG9900-2005" TOTAL_1="168" TOTAL_2="167" VAR="33.59" WEIGHT="25.176135511917252"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.0748829944439762" CI_END="1.0763104193631505" CI_START="0.5865537602057505" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7945526562954051" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.03193754454023277" LOG_CI_START="-0.23169217674417442" LOG_EFFECT_SIZE="-0.09987731610197084" NO="2" P_CHI2="0.898236555308317" P_Q="1.0" P_Z="0.13752197191134785" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="152" WEIGHT="99.99999999999999" Z="1.4850824973653198">
<NAME>Hazard ratio plot for overall survival (sensitivity analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.9271922614544668" CI_START="0.36551861997408325" EFFECT_SIZE="1.0343806242412183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.4664512483465254" LOG_CI_START="-0.4370904946403902" LOG_EFFECT_SIZE="0.01468037685306762" ORDER="1" O_E="0.12" SE="0.5307448924342753" STUDY_ID="STD-Dautzenberg-1990" TOTAL_1="13" TOTAL_2="13" VAR="3.55" WEIGHT="8.513189448441246"/>
<IPD_DATA CI_END="1.880947578039979" CI_START="0.4174194922007471" EFFECT_SIZE="0.8860836207049948" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.27437669194313985" LOG_CI_START="-0.37942727458640435" LOG_EFFECT_SIZE="-0.05252529132163224" ORDER="2" O_E="-0.82" SE="0.3840476863212843" STUDY_ID="STD-Roth-1994" TOTAL_1="28" TOTAL_2="32" VAR="6.78" WEIGHT="16.258992805755394"/>
<IPD_DATA CI_END="1.2078784039340675" CI_START="0.3133515936450003" EFFECT_SIZE="0.6152159155955895" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.08202321643870633" LOG_CI_START="-0.5039680922214865" LOG_EFFECT_SIZE="-0.21097243789139009" ORDER="3" O_E="-4.1" SE="0.3442141954107571" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="8.44" WEIGHT="20.239808153477213"/>
<IPD_DATA CI_END="1.3049813788442566" CI_START="0.42715669920869875" EFFECT_SIZE="0.746613379411278" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11560431464526982" LOG_CI_START="-0.36941277809522216" LOG_EFFECT_SIZE="-0.12690423172497617" ORDER="4" O_E="-3.6" SE="0.2849014411490949" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="31" TOTAL_2="31" VAR="12.32" WEIGHT="29.544364508393283"/>
<IPD_DATA CI_END="1.6315917150066166" CI_START="0.4897438728581821" EFFECT_SIZE="0.8939027046780111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.21261149136432372" LOG_CI_START="-0.3100309887186818" LOG_EFFECT_SIZE="-0.04870974867717906" ORDER="5" O_E="-1.19" SE="0.3070027799227584" STUDY_ID="STD-Sorensen-2005" TOTAL_1="44" TOTAL_2="46" VAR="10.61" WEIGHT="25.44364508393285"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.1412094492000533" CI_END="0.9720124706835394" CI_START="0.6923943770464825" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.8203755049490091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.012328163145429229" LOG_CI_START="-0.15964646769959065" LOG_EFFECT_SIZE="-0.08598731542250991" NO="3" P_CHI2="0.9796889589087113" P_Q="0.9416161786474891" P_Z="0.022137599431960333" Q="0.12031509546916186" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="495" WEIGHT="99.99999999999997" Z="2.2879986552308496">
<NAME>Hazard ratio plot for overall survival by chemotherapy grouping</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.3388428904353041" CI_END="1.248547330448446" CI_START="0.5478949600777421" DF="2.0" EFFECT_SIZE="0.8270869299966134" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.0964050104142154" LOG_CI_START="-0.2613026944922713" LOG_EFFECT_SIZE="-0.08244884203902791" NO="1" P_CHI2="0.8441530925483879" P_Z="0.3662537608252383" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="76" WEIGHT="16.96121012430732" Z="0.903512889138197">
<NAME>Platinum + vinca alkaloid / etoposide</NAME>
<IPD_DATA CI_END="2.9271922614544668" CI_START="0.36551861997408325" EFFECT_SIZE="1.0343806242412183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.4664512483465254" LOG_CI_START="-0.4370904946403902" LOG_EFFECT_SIZE="0.01468037685306762" ORDER="1" O_E="0.12" SE="0.5307448924342753" STUDY_ID="STD-Dautzenberg-1990" TOTAL_1="13" TOTAL_2="13" VAR="3.55" WEIGHT="2.658379511756776"/>
<IPD_DATA CI_END="1.3049813788442566" CI_START="0.42715669920869875" EFFECT_SIZE="0.746613379411278" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11560431464526982" LOG_CI_START="-0.36941277809522216" LOG_EFFECT_SIZE="-0.12690423172497617" ORDER="2" O_E="-3.6" SE="0.2849014411490949" STUDY_ID="STD-Roth-1994" TOTAL_1="31" TOTAL_2="31" VAR="12.32" WEIGHT="9.225700164744644"/>
<IPD_DATA CI_END="1.880947578039979" CI_START="0.4174194922007471" EFFECT_SIZE="0.8860836207049948" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.27437669194313985" LOG_CI_START="-0.37942727458640435" LOG_EFFECT_SIZE="-0.05252529132163224" ORDER="3" O_E="-0.82" SE="0.3840476863212843" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="28" TOTAL_2="32" VAR="6.78" WEIGHT="5.0771304478059"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.031293641312404336" CI_END="1.1448849719055296" CI_START="0.6348867162387057" DF="1.0" EFFECT_SIZE="0.8525680385072762" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.05876185473164125" LOG_CI_START="-0.19730375959218086" LOG_EFFECT_SIZE="-0.06927095243026984" NO="2" P_CHI2="0.8595869097993764" P_Z="0.2889535029227268" STUDIES="2" TAU2="0.0" TOTAL_1="212" TOTAL_2="213" WEIGHT="33.098697019619586" Z="1.0604201762632794">
<NAME>Platinum + taxane</NAME>
<IPD_DATA CI_END="1.6315917150066166" CI_START="0.4897438728581821" EFFECT_SIZE="0.8939027046780111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.21261149136432372" LOG_CI_START="-0.3100309887186818" LOG_EFFECT_SIZE="-0.04870974867717906" ORDER="1" O_E="-1.19" SE="0.3070027799227584" STUDY_ID="STD-Sorensen-2005" TOTAL_1="44" TOTAL_2="46" VAR="10.61" WEIGHT="7.945184963306872"/>
<IPD_DATA CI_END="1.1778839369590117" CI_START="0.5989166003991823" EFFECT_SIZE="0.8399132355120356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.07110249926132672" LOG_CI_START="-0.22263364924364623" LOG_EFFECT_SIZE="-0.07576557499115974" ORDER="2" O_E="-5.86" SE="0.17254206764920632" STUDY_ID="STD-SWOG9900-2005" TOTAL_1="168" TOTAL_2="167" VAR="33.59" WEIGHT="25.153512056312714"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.6507578219831831" CI_END="1.013827509420762" CI_START="0.6273351246374628" DF="1.0" EFFECT_SIZE="0.7975021046889859" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.0059640712901714785" LOG_CI_START="-0.20250039553428809" LOG_EFFECT_SIZE="-0.09826816212205833" NO="3" P_CHI2="0.4198421417398053" P_Z="0.06462886834163663" STUDIES="2" TAU2="0.0" TOTAL_1="209" TOTAL_2="206" WEIGHT="49.94009285607308" Z="1.8478166713021722">
<NAME>Other platinum regimen</NAME>
<IPD_DATA CI_END="1.2078784039340675" CI_START="0.3133515936450003" EFFECT_SIZE="0.6152159155955895" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.08202321643870633" LOG_CI_START="-0.5039680922214865" LOG_EFFECT_SIZE="-0.21097243789139009" ORDER="1" O_E="-4.1" SE="0.3442141954107571" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="8.44" WEIGHT="6.32020368428935"/>
<IPD_DATA CI_END="1.070508202982253" CI_START="0.6405215276149929" EFFECT_SIZE="0.8280601122494511" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.029589999511146887" LOG_CI_START="-0.19346626924906055" LOG_EFFECT_SIZE="-0.08193813486895686" ORDER="2" O_E="-10.99" SE="0.13102435641608368" STUDY_ID="STD-Depierre-2002" TOTAL_1="179" TOTAL_2="176" VAR="58.25" WEIGHT="43.619889171783726"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.1412094492000524" CI_END="0.9720124706835394" CI_START="0.6923943770464825" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.8203755049490091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.012328163145429229" LOG_CI_START="-0.15964646769959065" LOG_EFFECT_SIZE="-0.08598731542250991" NO="4" P_CHI2="0.9796889589087113" P_Q="0.5118057613211717" P_Z="0.022137599431960333" Q="0.4303734867485173" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="495" WEIGHT="100.0" Z="2.2879986552308496">
<NAME>Hazard ratio plot for overall survival by disease stage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.20382470153216004" CI_END="1.0215406481755267" CI_START="0.6980775113087029" DF="3.0" EFFECT_SIZE="0.844461102348149" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.009255652345955169" LOG_CI_START="-0.15609635264229993" LOG_EFFECT_SIZE="-0.07342035014817237" NO="1" P_CHI2="0.976969522412811" P_Z="0.08176349448356814" STUDIES="4" TAU2="0.0" TOTAL_1="404" TOTAL_2="402" WEIGHT="79.37696570316011" Z="1.7405442653442174">
<NAME>All stages of patients included</NAME>
<IPD_DATA CI_END="2.9271922614544668" CI_START="0.36551861997408325" EFFECT_SIZE="1.0343806242412183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.4664512483465254" LOG_CI_START="-0.4370904946403902" LOG_EFFECT_SIZE="0.01468037685306762" ORDER="1" O_E="0.12" SE="0.5307448924342753" STUDY_ID="STD-Dautzenberg-1990" TOTAL_1="13" TOTAL_2="13" VAR="3.55" WEIGHT="2.658379511756777"/>
<IPD_DATA CI_END="1.070508202982253" CI_START="0.6405215276149929" EFFECT_SIZE="0.8280601122494511" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.029589999511146887" LOG_CI_START="-0.19346626924906055" LOG_EFFECT_SIZE="-0.08193813486895686" ORDER="2" O_E="-10.99" SE="0.13102435641608368" STUDY_ID="STD-Depierre-2002" TOTAL_1="179" TOTAL_2="176" VAR="58.25" WEIGHT="43.61988917178374"/>
<IPD_DATA CI_END="1.6315917150066166" CI_START="0.4897438728581821" EFFECT_SIZE="0.8939027046780111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.21261149136432372" LOG_CI_START="-0.3100309887186818" LOG_EFFECT_SIZE="-0.04870974867717906" ORDER="3" O_E="-1.19" SE="0.3070027799227584" STUDY_ID="STD-Sorensen-2005" TOTAL_1="44" TOTAL_2="46" VAR="10.61" WEIGHT="7.9451849633068745"/>
<IPD_DATA CI_END="1.1778839369590117" CI_START="0.5989166003991823" EFFECT_SIZE="0.8399132355120356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.07110249926132672" LOG_CI_START="-0.22263364924364623" LOG_EFFECT_SIZE="-0.07576557499115974" ORDER="4" O_E="-5.86" SE="0.17254206764920632" STUDY_ID="STD-SWOG9900-2005" TOTAL_1="168" TOTAL_2="167" VAR="33.59" WEIGHT="25.15351205631272"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.5070112609193751" CI_END="1.0662104782670432" CI_START="0.5051766360660003" DF="2.0" EFFECT_SIZE="0.7339105005034784" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.027842946272977925" LOG_CI_START="-0.29655674335472854" LOG_EFFECT_SIZE="-0.1343568985408753" NO="2" P_CHI2="0.7760753859501592" P_Z="0.10447830445606855" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="93" WEIGHT="20.623034296839897" Z="1.6235199393490836">
<NAME>Only stage III patients included</NAME>
<IPD_DATA CI_END="1.880947578039979" CI_START="0.4174194922007471" EFFECT_SIZE="0.8860836207049948" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.27437669194313985" LOG_CI_START="-0.37942727458640435" LOG_EFFECT_SIZE="-0.05252529132163224" ORDER="1" O_E="-0.82" SE="0.3840476863212843" STUDY_ID="STD-Roth-1994" TOTAL_1="28" TOTAL_2="32" VAR="6.78" WEIGHT="5.077130447805901"/>
<IPD_DATA CI_END="1.2078784039340675" CI_START="0.3133515936450003" EFFECT_SIZE="0.6152159155955895" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.08202321643870633" LOG_CI_START="-0.5039680922214865" LOG_EFFECT_SIZE="-0.21097243789139009" ORDER="2" O_E="-4.1" SE="0.3442141954107571" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="8.44" WEIGHT="6.320203684289352"/>
<IPD_DATA CI_END="1.3049813788442566" CI_START="0.42715669920869875" EFFECT_SIZE="0.746613379411278" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11560431464526982" LOG_CI_START="-0.36941277809522216" LOG_EFFECT_SIZE="-0.12690423172497617" ORDER="3" O_E="-3.6" SE="0.2849014411490949" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="31" TOTAL_2="31" VAR="12.32" WEIGHT="9.225700164744646"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.0748829944439757" CI_END="1.0763104193631503" CI_START="0.5865537602057505" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7945526562954051" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.03193754454023268" LOG_CI_START="-0.23169217674417442" LOG_EFFECT_SIZE="-0.09987731610197084" NO="5" P_CHI2="0.8982365553083171" P_Q="0.5477756730489098" P_Z="0.13752197191134782" Q="0.36131751728183936" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="152" WEIGHT="100.0" Z="1.48508249736532">
<NAME>Hazard ratio plot for survival by post-operative treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.6577697541767873" CI_END="1.0688101323595847" CI_START="0.5308214561543699" DF="2.0" EFFECT_SIZE="0.7532246350270678" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.02890056227873664" LOG_CI_START="-0.275051530982588" LOG_EFFECT_SIZE="-0.12307548435192571" NO="1" P_CHI2="0.719725930886439" P_Z="0.11245672473848149" STUDIES="3" TAU2="0.0" TOTAL_1="105" TOTAL_2="107" WEIGHT="75.22781774580336" Z="1.5872469514608936">
<NAME>Post-operative radiotherapy</NAME>
<IPD_DATA CI_END="1.2078784039340675" CI_START="0.3133515936450003" EFFECT_SIZE="0.6152159155955895" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.08202321643870633" LOG_CI_START="-0.5039680922214865" LOG_EFFECT_SIZE="-0.21097243789139009" ORDER="1" O_E="-4.1" SE="0.3442141954107571" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="8.44" WEIGHT="20.23980815347722"/>
<IPD_DATA CI_END="1.3049813788442566" CI_START="0.42715669920869875" EFFECT_SIZE="0.746613379411278" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11560431464526982" LOG_CI_START="-0.36941277809522216" LOG_EFFECT_SIZE="-0.12690423172497617" ORDER="2" O_E="-3.6" SE="0.2849014411490949" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="31" TOTAL_2="31" VAR="12.32" WEIGHT="29.54436450839329"/>
<IPD_DATA CI_END="1.6315917150066166" CI_START="0.4897438728581821" EFFECT_SIZE="0.8939027046780111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.21261149136432372" LOG_CI_START="-0.3100309887186818" LOG_EFFECT_SIZE="-0.04870974867717906" ORDER="3" O_E="-1.19" SE="0.3070027799227584" STUDY_ID="STD-Sorensen-2005" TOTAL_1="44" TOTAL_2="46" VAR="10.61" WEIGHT="25.443645083932854"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.05579572298534903" CI_END="1.7195299403725244" CI_START="0.5078452252461961" DF="1.0" EFFECT_SIZE="0.9344811768495195" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.235409742138474" LOG_CI_START="-0.2942686264235227" LOG_EFFECT_SIZE="-0.029429442142524333" NO="2" P_CHI2="0.8132688041192244" P_Z="0.8275888508001374" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="45" WEIGHT="24.772182254196643" Z="0.21779498695046928">
<NAME>Post-operative chemotherapy</NAME>
<IPD_DATA CI_END="2.9271922614544668" CI_START="0.36551861997408325" EFFECT_SIZE="1.0343806242412183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.4664512483465254" LOG_CI_START="-0.4370904946403902" LOG_EFFECT_SIZE="0.01468037685306762" ORDER="1" O_E="0.12" SE="0.5307448924342753" STUDY_ID="STD-Dautzenberg-1990" TOTAL_1="13" TOTAL_2="13" VAR="3.55" WEIGHT="8.513189448441247"/>
<IPD_DATA CI_END="1.880947578039979" CI_START="0.4174194922007471" EFFECT_SIZE="0.8860836207049948" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.27437669194313985" LOG_CI_START="-0.37942727458640435" LOG_EFFECT_SIZE="-0.05252529132163224" ORDER="2" O_E="-0.82" SE="0.3840476863212843" STUDY_ID="STD-Roth-1994" TOTAL_1="28" TOTAL_2="32" VAR="6.78" WEIGHT="16.258992805755398"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Disease-free survival</NAME>
<IPD_OUTCOME CHI2="5.416080714434439" CI_END="0.9874176617036174" CI_START="0.6171796740234865" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.7806498002147133" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="63.0729284615389" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.005499108925458168" LOG_CI_START="-0.20958838527382406" LOG_EFFECT_SIZE="-0.10754374709964115" NO="1" P_CHI2="0.06666751205913868" P_Q="1.0" P_Z="0.03886768463742436" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="228" WEIGHT="100.0" Z="2.0655849719217074">
<NAME>Hazard ratio plot for disease-free survival</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="0.8207305803165458" CI_START="0.27855952538008216" EFFECT_SIZE="0.4781446652613583" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="-0.08579938451838157" LOG_CI_START="-0.5550819861929521" LOG_EFFECT_SIZE="-0.32044068535566683" ORDER="1" O_E="-9.71" SE="0.27565892320998564" STUDY_ID="STD-Rosell-1994" TOTAL_1="30" TOTAL_2="30" VAR="13.16" WEIGHT="18.913480885311873"/>
<IPD_DATA CI_END="2.029392691802249" CI_START="0.685946549155534" EFFECT_SIZE="1.179853767982801" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.30736609207101917" LOG_CI_START="-0.16370972439704928" LOG_EFFECT_SIZE="0.07182818383698501" ORDER="2" O_E="2.16" SE="0.27671226645624275" STUDY_ID="STD-JCOG9209-2003" TOTAL_1="31" TOTAL_2="31" VAR="13.06" WEIGHT="18.76976142569704"/>
<IPD_DATA CI_END="1.0772387996513497" CI_START="0.5939883543773931" EFFECT_SIZE="0.7999170593732725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.03231198730447444" LOG_CI_START="-0.2262220696302806" LOG_EFFECT_SIZE="-0.09695504116290304" ORDER="3" O_E="-9.68" SE="0.15186418480769676" STUDY_ID="STD-SWOG9900-2005" TOTAL_1="168" TOTAL_2="167" VAR="43.36" WEIGHT="62.31675768899109"/>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan">
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-09-18 22:42:04 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Begg's Funnel Plot.</P>
<P>Beggs funnel plot for publication bias</P>
<P>Begg's Test<BR/>adj. Kendall's Score (P-Q)= 7<BR/>Std. Dev. of Score= 6.66 <BR/>Number of Studies= 7<BR/>z = 1.05<BR/>Pr &gt; z = 0.293<BR/>z = 0.90(continuity corrected)<BR/>Pr &gt; z = 0.368(continuity corrected)</P>
<P>Egger's test<BR/>Std_EffCoef.Std. Err.TP&gt;t[95% Conf.Interval]<BR/>Slope-.1912817.095858-2.000.103-.4376924.0551291<BR/>Bias-.0324864.4186826-0.080.941-1.1087441.043771<BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAj4AAAFpCAIAAAATM7UpAAAJbklEQVR42u3d4VLjOrqG0Vx83zdN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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>